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Abstract
We have successfully truncated and recombinantly-expressed 1-deoxy-D-xylulose-5-phosphate 
synthase (DXS) from both P. vivax and P. falciparum. We elucidated the order of substrate 
binding for both of these ThDP-dependent enzymes using steady-state kinetic analyses, dead-end 
inhibition, and intrinsic tryptophan fluorescence titrations. Both enzymes adhere to a random 
sequential mechanism with respect to binding of both substrates: pyruvate and D-
glyceraldehyde-3-phosphate. These findings are in contrast to other ThDP-dependent enzymes, 
which exhibit classical ordered and/or ping-pong kinetic mechanisms. A better understanding of 
the kinetic mechanism for these two Plasmodial enzymes could aid in the development of novel 
DXS-specific inhibitors that might prove useful in treatment of malaria.
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1. Introduction
Malaria is a life-threatening, infectious disease caused by parasites of the genus 
Plasmodium, transmitted through the bite of an infected female Anopheles mosquito. 
Malaria afflicts nearly 100 countries worldwide, with estimates of 198 million cases in 2013, 
resulting in 584,000 deaths. [1] Malaria poses a risk to roughly half of the population on 
earth, and infections are on the rise due to global warming, deforestation, and drug and 
insecticide resistance. [1–5] In humans, malaria is caused by an infection by one of five 
Plasmodium species: P. falicparum, P. vivax, P. ovale, P. malariae, and P. knowlesi. P. 
falciparum malaria, constituting approximately 75% of the reported cases, is the most 
deadly form of malaria; however, P. vivax malaria, constituting approximately 20% of the 
reported cases, is serious and more widespread. [1, 6]
Isoprenoids (or terpenoids) constitute one of the largest classes of complex, biologically-
active compounds, which serve diverse roles, functioning as cholesterol, hormones, fat-
soluble hormones, carotenoids, pigments, and chlorophyll. [7–9] Isoprene is a five-carbon 
skeleton that is the precursor of all isoprenoids through rearrangement, cyclization, and 
oxidation. [10] Yet, isoprene itself is not used for the production of isoprenoids in vivo; 
instead the biological forms of isoprene are the two branched, phosphorylated five-carbon 
precursors, dimethylallyl diphosphate (DMAPP) and isopentyl diphosphate (IPP). For half a 
century, it was thought that the sole biosynthetic pathway of isoprenoid production was via 
the mevalonate pathway. [11] However, in 1996, Rohmer et al. [12] discovered that certain 
eubacteria, parasites, and several plants produce isoprenoids from a mevalonate-independent 
pathway. This biosynthetic route, known as the 2-C-methyl-D-erythritol 4-phosphate (MEP) 
pathway, produces DMAPP and IPP from a set of orthogonal enzymes nonexistent in higher 
organisms and mammals. The MEP pathway, therefore, represents a platform for the 
development of novel herbicides, antimalarials, and antibiotics to aid the treatment of human 
disease. [13–16]
In Plasmodium parasites, as well as other organisms from the phylum Apicomplexa, the 
MEP pathway produces DMAPP and IPP over seven successive enzymatic reactions. The 
first committed step of the pathway is catalyzed by 1-deoxy-D-xyluose-5-phosphate 
reductoisomerase (DXR), which involves the NADPH-dependent rearrangement and two 
electron reduction of the linear 1-deoxy-D-xylulose-5-phosphate (DXP) to the branched-
chain isoprenoid precursor MEP. However, the enzyme catalyzing the first reaction of the 
pathway is also an attractive target for inhibitor development, 1-deoxy-D-xylulose-5-
phosphate synthase (DXS). DXS catalyzes the condensation of pyruvate and D-
glyceraldehyde-3-phosphate (GAP) to produce CO2 and 1-deoxy-D-xylulose-5-phosphate 
(DXP), a reaction that is the rate-limiting for the MEP pathway in several organisms as well 
as the branch point for B vitamin and isoprenoid biosynthesis. [17] DXS belongs to the 
family of enzymes that utilizes thiamine diphosphate (ThDP) as a co-factor, and shares high 
homology with human transketolase, pyruvate dehydrogenase, and pyruvate decarboxylase. 
[18–20] Like these other ThDP-dependent enzymes, DXS catalyzes decarboxylation and 
carboligation chemistry: a two-carbon intermediate bound to ThDP (hydroxyethyl-ThDP) is 
condensed with an acceptor substrate (GAP) via nucleophilic addition to generate a new 
carbon-carbon bond yielding DXP.
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All ThDP-dependent enzymes catalyze two successive half reactions. [21] The first step 
involves the attack of an activated ThDP ylide on the first substrate. [22] The next step could 
occur via three distinct mechanisms. The most common is the classical ping-pong 
mechanism, in which the first product is released, forming a metastable enzyme-
intermediate complex. Product formation follows after binding of the second substrate. 
Every ThDP-dependent enzyme studied to date follows this mechanism, and has also been 
proposed for DXS from E. coli and H. influenza. [23] Another possibility for the second half 
reaction proceeds through an ordered mechanism, where the first product can only be 
released after the second substrate is bound to the active site. The first substrate binds tightly 
and essentially irreversibly, while the second substrate can only bind to a pocket opened in 
the presence of the first substrate. Carbon dioxide (CO2) trapping studies on R. capsulatus 
DXS performed by Eubanks and Poulter suggested an ordered sequential kinetic 
mechanism. [24] The results of the experiment indicated that pyruvate bound first and 
irreversibly, followed by binding of GAP to form a ternary complex, and, finally, the release 
CO2 and DXP in that order. However, subsequent work demonstrating that DXS will 
catalyze the conversion of pyruvate to acetolatate and CO2 at high pyruvrate concentrations 
suggests that the kinetic mechanism for R. capsulatus DXS is not sequential. [25, 26]
The third potential mechanism that DXS could display is a random sequential mechanism, in 
which binding of both substrates is reversible and independent. Brammer et al. [25, 27] have 
proposed an unprecedented rapid equilibrium, random sequential mechanism for E. coli 
DXS, which is in contrast to all known ThDP-dependent enzymes to date. [28] Binding of 
either pyruvate or GAP is independent of the other, and GAP is required for the release of 
CO2 and the formation of a kinetically competent ternary structure. They suggest formation 
of the lactyl-ThDP intermediate is the overall rate-limiting step and it is maintained in a low-
reactive state. GAP binding induces a reorientation to provide the optimal dihedral angle for 
decarboxylation. [29]
We report, herein, on the successful production of recombinant, catalytically active forms of 
Plasmodium falciparum DXS and Plasmodium vivax DXR. Similar to earlier work on the 
expression of P. vivax DXS [30] and P. falciparum DXR, [31] the catalytically active forms 
of P. falciparum DXS and P. vivax DXR have been truncated to their respective catalytic 
cores, lacking the signaling and transit peptide for each of these enzymes. In addition to 
recombinant P. falciparum DXS and P. vivax DXR, we also produced the truncated forms of 
P. vivax DXS and P. falciparum DXR in E. coli by following published protocols. Both P. 
falciparum and P. vivax DXS enzymes were characterized via steady-state kinetic analyses, 
intrinsic tryptophan fluorescence titrations, and dead-end inhibition studies employing a pair 
of pyruvate mimics. DXS activity was measured using a DXR-dependent coupled assay, 
pairing P. falciparum DXS with P. falciparum DXR or P. vivax DXS with P. vivax DXR. 
Our characterization of DXS from two Plasmodium species points toward a random 
sequential kinetic mechanism, an unusual finding for ThDP-dependent enzymes. This work 
fosters a deeper understanding of the DXS-catalyzed reaction and will aid in the rational 
design of DXS inhibitors for the treatment of malaria and other human diseases.
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2. Experimental Procedures
2.1. Materials and General Methods
Unless otherwise noted, all reagents were obtained from commercial sources. BL21 (DE3) 
E. coli cells and the pET-28a (+) vector were purchased from Novagen. PfuUltra High-
Fidelity DNA polymerase was purchased from Aglient. BamHI, XhoI, NdeI, Antarctic 
Phosphatase, and T4 DNA ligase were purchased from New England Biolabs. Kanamycin 
monosulfate and IPTG were purchased from Gold Biotechnology. Size exclusion 
chromatography was performed on a GE Healthcare AKTAprime Plus FPLC, coupled to a 
HiLoad 16/600 Superdex 200 pg column. Spectrophotometric analyses were performed on a 
Cary 300 Bio UV-Visibile spectrophotometer. Tryptophan fluorescence studies were 
performed on a JASCO FP-8300 spectrofluorometer.
2.2. Cloning of the P. falciparum dxs and P. vivax dxr Genes Without Signal and Transit 
Peptides
A synthetic, codon-optimized gene for P. falciparum dxs was purchased from Genscript. P. 
falciparum dxs was designed with 5’-NdeI and 3’-XhoI restriction sites and synthesized into 
a pUC57 vector. The full-length gene was excised from the pUC57 vector and cloned into 
the NdeI and XhoI restriction sites of the pET-28a vector. Similarly, a P. vivax dxr codon-
optimized gene was also purchased from Genscript, with 5’-NdeI and 3’-BamHI restriction 
sites in a pUC57 vector. P. vivax dxr was cloned into pET-28a using NdeI and BamHI 
restriction sites.
Truncated gene constructs were produced from the full length, codon-optimized genes using 
PCR extraction to eliminate expression of the N-terminal signal and transit peptides of both 
PfDXS and PvDXR. PfDXS-A, PfDXS-B, PfDXS-C, and PfDXS-D were produced with 
deletions of 237, 286, 292, and 310 amino acids, respectively. PvDXR-E, PvDXR-F, and 
PvDXR-G were constructed with 99, 106, and 110 amino acid deletions, respectively. The 
cloning of PvDXS was described previously. [30] The cloning of PfDXR has also been 
previously described, [31] and this gene was generously donated by Dr. Nobutada Tanaka at 
Showa University (Japan) for the use in this study.
2.3. Overexpression of Truncated DXS and DXR Proteins in E. coli
Truncated gene transcripts of DXS and DXR in pET-28a were transformed into E. coli 
BL-21 (DE3) cells. A fresh colony of cells harboring either truncated Pfdxs-pET-28a or 
Pvdxr-pET-28a were inoculated at 37 °C in LB broth containing 40 µg/mL kanamycin 
supplemented with 0.8% glucose and 25 mM potassium phosphate (pH = 7.2). The cultures 
were grown until the OD600 reached 0.3, then diluted 1:100. For the overexpression of 
PfDXS, cells were cultured until the OD600 reached 0.6, the temperature reduced to 10 °C, 
induced by the addition of 0.5 mM IPTG, and incubated overnight (12 hours) with 
continuous shaking. To produce PvDXR, the temperature was dropped to 30 °C after 
achieving an OD600 of 0.6, induction initiated with 1 mM IPTG, and overnight incubation. 
Cells were harvested by centrifugation, and the cell pellets stored at −80 °C. The expression 
of PvDXS [30] and PfDXR [31] were described previously.
Battistini et al. Page 4
Protein Expr Purif. Author manuscript; available in PMC 2017 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
2.4. Purification of DXS and DXR by Ni-NTA Affinity and Size-Exclusion Chromatography
Cells were thawed on ice and all purification steps were performed at 4 °C. Cell pellets (4 g) 
were resuspended in 20 mL of binding buffer supplemented with protease inhibitors: 20 mM 
Tris pH 7.5, 500 mM NaCl, 20 mM imidazole, 10 mM b-mercaptoethanol (BME), 1 mM 
phenylmethylsulfonyl fluoride (PMSF), 4 mg/mL leupeptin, 2 mg/mL pepstatin, and 43 mg 
of an E. coli-specific protease inhibitor cocktail (Sigma P8465). The cells were lysed via 
sonication, centrifuged at 16,000 × g for 20 minutes at 4 °C, and the recombinant enzyme-
containing soluble lysate was retained.
Purification of DXS and DXR was facilitated by the fusion of an N-terminal His6-tag to the 
active, truncated enzymes. The supernatant was applied to a borosilicate glass column (1.5 
cm × 5 cm) containing 5 mL of nickel-nitrilotriacetic acid (Ni-NTA) resin equilibrated with 
binding buffer. The non-bound proteins were first eluted with 5 column volumes (CVs) of 
binding buffer, then with 20 CVs of wash buffer (20 mM Tris pH 7.5, 500 mM NaCl, 60 
mM imidazole, and 10 mM BME) at a flow rate of 1 mL/minute. Tagged, recombinant 
enzyme was eluted with 2 CVs of elution buffer (20 mM Tris pH 7.5, 500 mM NaCl, 250 
mM imidazole, 10 mM BME) and concentrated to <3 mL using an Amicon stirred 
ultrafiltration cell in preparation for size exclusion chromatography (SEC). The concentrated 
sample was injected onto an AKTAprime FPLC coupled to a 16/600 Superdex column 
equilibrated with 50 mM Tris pH 7.5, 150 mM NaCl, and 10 mM BME. The flow rate for 
the SEC was set to 1 mL/min with a maximum pressure of 0.5 mPa. The concentration of 
the enzyme-containing fractions was determined using the Bradford assay and purity was 
assessed by a 10% SDS-PAGE gel visualized with Coomassie Brilliant Blue stain. Fractions 
containing purified enzyme were combined, glycerol added to a final concentration of 10% 
(w/v), and the aliquots were flash frozen in liquid nitrogen with subsequent storage at −80 
°C.
2.5. Kinetic Analyses
DXS activity from both P. falciparum and P. vivax was measured spectrophotometrically 
using DXR from its corresponding organism as a coupling enzyme as previously reported 
[32] with minor variations. The concentration of D-GAP was determined enzymatically 
from commercially available D,L-GAP using human GAPDH. [26] Throughout the 
manuscript, our use of “GAP” refers to the concentration of D-GAP in the D,L-GAP 
mixture. Reaction mixtures containing 100 mM HEPES pH 7.0, 100 mM NaCl, 1.5 mM 
MgCl2, 1 mg/mL BSA, 1 mM ThDP, 2 mM BME, 150 µM NADPH, GAP, and pyruvate 
were preincubated for 5 minutes at 37 °C. DXR was pipetted into the cuvette (0.2 mg/mL), 
100 nM of DXS was added to initiate the reaction, and the solution (750 µL total volume) 
was vigorously mixed before initializing the spectrophotomer software. Rates of NADPH 
consumption in the coupled step between DXS and DXR were monitored 
spectrophotometrically at 340 nm for 2 minutes (extinction coefficient of 6,220 M−1 cm−1 
for NADPH). The rates of NADPH depletion were used to calculate initial rates of DXP 
formation. The apparent kinetic constants were determined by fitting the resulting data to 
equation 1 using SigmaPlot 12.0: vo represents initial velocity, Vm,app is the apparent 
maximal velocity, Km,app is the apparent Michaelis constant, and [S] is the substrate 
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concentration. Assays were performed in triplicate and the uncertainty for the kcat,app and 
(kcat/Km)app values were calculated using equation 2, where σ is the standard error. [33]
Equation 1
Equation 2
To delineate between a sequential and classic ping-pong mechanism, double-reciprocal plots 
of the initial velocity data were generated for GAP and pyruvate in SigmaPlot 12.0. Non-
linear regression analysis of initial rates and model discrimination analyses were performed 
in WaveMetrics IGOR Pro 6. Initial velocities were determined by varying the concentration 
of one substrate, while holding the other substrate at a fixed concentration. GAP was 
evaluated between 3.5 µM and 16 µM, whereas pyruvate was tested at concentrations 
ranging from 50 µM to 250 µM. The resulting initial velocity data was fit to equation 3 for a 
rapid-equilibrium random Bi-Bi mechanism, where vo is the initial velocity, Vm is the 
maximal velocity, [A] is the concentration of substrate A, [B] is the concentration of 
substrate B, Kia is the dissociation constant for substrate A, Kb is the Michaelis constant for 
substrate B, and Ka is the Michaelis constant for substrate A.
Equation 3
2.6. Synthesis of Methylacetylphosphonate (MAP)
MAP was synthesized, as previously reported [25, 34–36], with minor variations. In a dry 
three-necked round bottom flask with a magnetic stir bar under positive N2 pressure, acetyl 
chloride (1.21 mL, 14 mmol, 1 eq) was cooled to 0 °C in an ice-water bath. Trimethyl 
phosphite (1.65 mL, 14 mmol, 1 eq) was slowly injected over a period of 3 hours, which 
resulted in evolution of MeCl. After full addition of trimethyl phosphite, the light-grey 
solution was allowed to warm to room temperature and stirred for an additional 8 hours. 
Unreacted reagents were removed under vacuum to afford acetylphosphonate dimethyl ester 
(DAP). 1.58 g recovered (10.4 mmol, 74% yield) as a pale grey oil. 1H NMR (400 MHz, 
CDCl3) δ 2.24 (d, J = 5.31 Hz, 3H, CH3), 3.61 (d, J = 10.69, 6H, OCH3). 13C NMR (400 
MHz, CDCl3): d= 208.1 (d, JP,C=169.8 Hz), 54.0 (d, 2JP,C=7.2 Hz, 2 C), 20.9 (d, 
2JP,C=36.0 Hz).
The recovered DAP (1.58 g, 10.4 mmol, 1 eq) was dissolved in dry acetone (10.4 mL), and 
the solution was slowly injected into a solution of sodium iodide (1.71 g, 11.5 mmol, 1.1 eq) 
in 6 mL dry acetone. The yellow reaction mixture was stirred overnight at room temperature 
after which the precipitate was filtered, triturated with dry acetone, and dried to yield 
purified MAP. 93% yield. 1H NMR (400 MHz, D20) δ 2.20 (3 H, d, J 9.8 Hz) and 3.69 (3 H, 
d, J 10.63 Hz). All NMR spectra of isolated compounds are in agreement with literature 
reports.
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2.7. Inhibition of DXS with β-Fluorpyruvate and Methylacetylphosphonate
The varying inhibition patterns of DXS activity were measured with the DXS-DXR coupled 
assay in the presence of either β-fluorpyruvate or methylacetylphosphonate (MAP). Inhibitor 
concentrations were based upon previously established IC50 values (data not shown) and 
added to the kinetic reaction mixtures described above. For PvDXS, the concentrations of β-
fluorpyruvate tested were 0, 35, and 75 µM, while MAP was analyzed at 0, 150, and 300 
µM. To test PfDXS inhibition, β-fluorpyruvate and MAP concentrations were held at 0, 50, 
100 µM and 0, 70, 140 µM, respectively. No inhibition of DXR by either inhibitor was 
observed. All assays were performed in triplicate, and the resulting data was fit to equations 
4 – 6 in SigmaPlot12.0 for competitive, noncompetitive, and uncompetitive inhibition, 
respectively. For equations 4 – 6, vo is the initial velocity, Vm,app is the apparent maximal 
velocity, Km,app is the apparent Michaelis constant, [S] is the substrate concentration, [I] is 
the inhibitor concentration, and Ki is the inhibition constant.
Equation 4
Equation 5
Equation 6
2.8. Intrinsic Tryptophan Fluorescence Measurements for the Determination of Binding 
Constants for DXS
To study the binding of pyruvate and GAP to DXS, intrinsic tryptophan fluorescence (ITF) 
quenching titrations were utilized. All reaction mixtures for ITF titrations contained 100 mM 
HEPES pH 7.0, 100 mM NaCl, 1.5 mM MgCl2, 2 mM BME, and 500 nM DXS in a final 
volume of 400 µL. Fluorescent emission spectra were acquired on a JASCO FP-8300 
spectrofluorometer at 25 °C. The excitation wavelength was set at 280 nm, and emission 
occurred between 290–300 nm. Spectra were measured in triplicate from 305 nm to 360 nm, 
using a scan speed of 50 nm/min, and both excitation and emission bandwidth set at 2.5 nm. 
Spectra were corrected by subtracting emission spectra from acquisitions containing no 
enzyme (blanks), and normalized by taking the ratio of the fluorescence emission intensity 
at the λmax relative to starting enzyme only samples. Data were fit to equation 7, where ΔF is 
the change in intrinsic fluorescence, ΔFmax is the maximum change of fluorescence at 
infinite ligand concentration, [L] is the ligand concentration, and Kd is the ligand 
dissociation constant.
Equation 7
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3. Results and Discussion
Malaria parasites and other infectious organisms of the phylum Apicomplexa possess the 
apicoplast, an endosymbiotic organelle similar to the chloroplast of plants and algae. [37] 
With a complete genome producing nearly 400 assorted proteins, the apicoplast is vital in 
various aspects of parasite metabolism including fatty acid and isoprenoid biosynthesis. All 
of the enzymes from the MEP pathway are nuclear-encoded and translocated to the 
apicoplast through a secretory pathway utilizing a bipartite N-terminal signaling motif. This 
sequence consists of two functional domains: an endoplasmic reticulum-targeting signal 
peptide and a transit peptide. The signal peptide directs the translocation of the enzyme into 
the secretory pathway, while the transit peptide facilitates the movement through the four 
outer membranes of the apicoplast. Once inside, the peptides are cleaved off (most likely by 
a stromal processing protease) to yield the catalytically-competent enzyme. [38]
To date, only a few enzymes targeted to the apicoplast from Plasmodium have been 
expressed, due in part to difficulties in obtaining soluble recombinant enzyme from E. coli 
host cells. [30, 39, 40] In addition to codon biases between E. coli and Plasmodium species 
(high GC content, ribosomal binding sites, random repeats of rare codons, etc), the presence 
of the signaling and transit motifs consistently result in the accumulation of insoluble 
inclusion bodies. [39] Therefore, serial deletion of the full-length, untruncated gene is 
required to produce a DXS or DXR variant that is soluble when expressed in E. coli. Several 
freely available algorithms (PlasmoAP [41], PATS [42], PSORT [43], etc.) have been 
developed, which have proven successful in identifying the signal peptide. Note that the 
signal peptide varies in length from 20–30 amino acids and exhibits a consensus sequence. 
In contrast, there is no consensus sequence or narrowly defined size for the transit peptide, 
which can vary from 50–500 amino acids, meaning that there are no current algorithms that 
can accurately predict this peptide region (see Figure 1 of the DXS amino acid sequence 
from several organisms with low N-terminal homology). [20] Malarial transit peptides can 
be approximated by the presence of highly enriched lysine and asparagine residues, which 
results in an overall positive charge. [41] This trend is pronounced in the amino acid 
sequence of P. falciparum DXS between residues ~150–300 (Figure 1, note the high number 
of successive asparagine residues).
By utilizing homology modeling and N-terminal serial deletions of the full-length codon-
optimized genes, several targeted variants of PfDXS and PvDXR were produced in our 
expression optimization study. PfDXS-A, PfDXS-B, PfDXS-C, and PfDXS-D were 
generated with N-terminal deletions of 237, 286, 292, and 310 amino acids, respectively. 
PvDXR-E, PvDXR-F, and PvDXR-G were constructed with N-terminal deletions of 99, 
106, and 110 amino acid deletions, respectively. Each of these genes was then transformed 
into BL-21 (DE3) E. coli expression cells, and cultured in 2 mL aliquots. These small-scale 
cultures were optimized for time of expression (1, 3, 5, and 12 hours), induction temperature 
(10, 25, 30, or 37 °C) and IPTG concentration (0.1, 0.5, or 1.0 mM) for a total of 48 culture 
conditions per truncated gene. The small scale cultures were then centrifuged, lysed via 
sonication, and the soluble proteome subjected to an anti-His6 Western blot antibody assay 
for the detection of recombinant enzyme. Only one truncated gene and one set of variables 
proved successful for each enzyme: PfDXS-D (with 310 amino acids deleted) was expressed 
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at 10 °C, induced by the addition of 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), 
and incubated overnight (12 hours) with continuous shaking. After subsequent purification 
via Ni-NTA affinity and size exclusion chromatography, the final yield of PfDXS-D was 1.4 
mg/L (Figure 2). To produce PvDXR, the protein construct with 110 amino acids removed 
(PvDXR-G) produced soluble enzyme at 30 °C with 1 mM IPTG and overnight incubation. 
PvDXR-G yielded 0.9 mg/L after both affinity and size exclusion chromatography (Figure 
3). This enzyme was used in the DXS-DXR coupled assay to further study PvDXS (kinetic 
constants of PvDXR-G: Km = 48 ± 1.6 µM, Vm = 1.3 ± 0.01 s−1, kcat/Km = (2.7 ± 0.1) × 104 
M−1s−1. These values are in good agreement with previously published data for DXR from 
several other organisms. [44–47] The cloning, expression, and characterization of PfDXR 
[31] and PvDXS [30] were previously described. From this point forth, PfDXS-D and 
PvDXR-G will simply be referred to as PfDXS and PvDXR, respectively.
Once both sets of enzymes were cloned, expressed, and purified, we set about to elucidate 
kinetic and binding characteristics of DXS from P. falciparum and P. vivax. For the 
determination of kinetic constants, initial velocities of DXP formation were monitored using 
the DXS-DXR coupled assay at sub-saturating concentrations of one substrate, while 
holding the other fixed. Rates were determined in triplicate. Binding constants were 
obtained using intrinsic tryptophan fluorescence titrations, and the results of both of these 
experiments are detailed in Table 1.
The kinetic constants for both P. falciparum DXS and P. vivax DXS are comparable to 
previously published data for DXS from E. coli, R. capsulatas, and D. radiodurans. The Kd 
values for both Plasmodium enzymes are also commensurate with the dissociation constants 
for E. coli DXS (see Figures 4 and 5). Clues of the binding mechanism can be delineated 
from these data: in the ordered mechanism with pyruvate binding first and, irreversibly, 
binding of pyruvate causes a conformational change which promotes binding of GAP. 
Binding of GAP to free enzyme should, therefore, be negligible. [25] However, a 
measurable binding constant for pyruvate to both PfDXS and PvDXS suggests that pyruvate 
binding is, in fact reversible, inconsistent with an ordered mechanism. In the proposed ping-
pong mechanism, GAP will have low affinity for the free enzyme. However, again, we 
observed quenching of the fluorescent signal indicative of GAP binding reversibly to both of 
the Plasmodium DXS enzymes. These data are inconsistent with a ping-pong mechanism. 
Taken together, the intrinsic fluorescence data supports a random sequential mechanism 
where GAP and pyruvate can both bind reversibly and independently to either P. falciparum 
or P. vivax DXS.
Also noted in our ITF data is an apparent Stokes shift in the wavelength for maximum 
fluorescence intensity when DXS is incubated with high concentrations of GAP, which was 
not found at similarly high levels of pyruvate (Figure 4). Tryptophan fluorescence is 
commonly used to monitor perturbations in protein dynamics and localized structures; 
fluorescence from tryptophan is sensitive to the polarity of its local environment. [48] 
Therefore, this apparent Stokes shift suggests that GAP binding induces a conformation 
change in DXS, at least within the vicinity of the fluorescent tryptophan residue. This 
represents the first report of a conformational change in DXS upon substrate binding. 
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Additional data for other DXS enzymes is required to determine the significance of our 
observation.
Double-reciprocal plots were generated to differentiate between a sequential binding 
mechanism and a ping-pong mechanism for both of the DXS enzymes from Plasmodium 
(Figures 6 and 7). The Lineweaver-Burk plots for both GAP and pyruvate had 
noncompetitive pattern with changes in both slope and intercept, suggesting a random 
sequential mechanism. If substrate binding to DXS were ordered, a competitive pattern for 
GAP would result and an uncompetitive pattern for pyruvate would be observed. Substrate 
inhibition was found at higher concentrations of both pyruvate and GAP (as evidenced by 
the converging lines), similar to what was reported by Brammer, et al. [25] for E. coli DXS. 
The data was further evaluated using global non-linear regression analysis: several 
mechanistic models for a two substrate, two product (Bi Bi) system were examined in a 
model discrimination analysis (rapid-equilibrium ordered, rapid-equilibrium random, ping-
pong, etc). The data were best fit to the equations for a random sequential mechanism 
(Figures 8 and 9).
Finally, inhibition studies were conducted to further confirm the mechanism of substrate 
binding to DXS. Both β-fluoropyruvate and MAP have been previously used as pyruvate 
mimics to study ThDP-dependent enzyme mechanisms. [34, 49–51] After ThDP activation, 
β-fluoropyruvate undergoes a catalytic step to release CO2 with consequent elimination of 
fluoride; therefore, it is not representative of a true dead-end inhibitor against pyruvate. 
MAP cannot undergo decaboxylation, and is, accordingly, a more suitable pyruvate analog. 
[25] Initial rates of DXP production were monitored using the DXS-DXR coupled assay at 
sub-saturating, varied concentrations of one substrate at fixed concentrations of the second 
substrate, in the presence of either inhibitor at varied concentrations. The equations for 
competitive, noncompetitive, and uncompetitive inhibition were fit to the data, and the 
results of the best fits are shown in Figures 10 and 11. For the pair of DXS enzymes, both 
MAP and β-fluoropyruvate displayed competitive inhibition against pyruvate, while 
exhibiting noncompetitive inhibition versus GAP (Table 2). This pattern of results is most 
consistent with a random sequential binding mechanism for both substrates to DXS. 
Conversely, a ping-pong mechanism would yield an uncompetitive pattern with respect to 
GAP.
4. Conclusion
The first two enzymes of the MEP pathway in the malaria-causing protists Plasmodium 
vivax and Plasmodium falciparum are DXS and DXR, respectively. Catalytically active, 
truncated forms of all four enzymes have been cloned and over-expressed in E. coli: P. 
falciparum DXS (described herein), P. falciparum DXR by Umeda et al.26, P. vivax DXS by 
Handa et al.25, and P. vivax DXR (described herein). Because of the metabolic centrality of 
the isoprenoids, the availability of DXS and DXR from P. falciparum and P. vivax should 
facilitate the development of novel anti-malarials targeted against either of these enzymes. 
The kinetic mechanism for DXS has proven controversial, with the majority of the published 
data pointing towards a random sequential mechanism. [25, 27, 28] Such a mechanism is 
unusual for a ThDP-dependent enzyme, as the first substrate typically forms an adduct with 
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the thiazolium moiety of ThDP. [21, 22, 27] yielding either an ordered or ping-pong kinetic 
mechanism. Our characterization of PfDXS and PvDXS, steady-state kinetic analyses, 
substrate binding studies, and dead-end inhibition experiments, are most consistent with a 
random sequential mechanism for both enzymes. The expression of PfDXS and PvDXS in 
E. coli, providing straightforward access to multi-milligram amounts of protein and fostering 
the construction of site-directed mutants, will enable the detailed structure-function studies 
to better understand the unique aspects of ThDP-dependent chemistry of DXS.
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Highlights
• The novel truncation and expression of Plasmodium falciparum DXS and 
Plasmodium vivax DXR.
• Enzymatic characterization by steady-state kinetics, inhibition, and binding 
constants.
• Confirmed previous reports of a random sequential binding mechanism for both 
Plasmodium falciparum and Plasmodium vivax DXS.
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Figure 1. 
Homology overlays of the N-terminal amino acid sequence for Plasmodium vivax, 
Plasmodium knowlesi, Plasmodium cynomolgi and Plasmodium falciparum.
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Figure 2. 
Purification scheme of Plasmodium falciparum DXS.
(A) Size-exclusion chromatography elution profile versus enzymatic activity.
(B) SDS-PAGE of the purification workflow
1. Molecular weight ladder
2. Nickel-column binding fraction
3. Nickel-column wash fraction
4. Nickel-column elution fraction
5. Size-exclusion column load
6. Size-exclusion column -purified PfDXS
7. MagicMark XP Western blot molecular weight ladder
(C) Western blot of the purification workflow
1. Molecular weight ladder
2. Nickel-column binding fraction
3. Nickel-column wash fraction
4. Nickel-column elution fraction
5. Size-exclusion column load
6. Size-exclusion column -purified PfDXS
7. MagicMark XP Western blot molecular weight ladder
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Figure 3. 
Purification scheme of Plasmodium vivax DXR.
(A) Same as A above
(B) Same as B above
(C) Same as C above
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Figure 4. 
Substrate-binding analysis of PvDXS by intrinsic-tryptophan quenching titrations with 
increasing [pyruvate] and [GAP].
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Figure 5. 
Substrate-binding analysis of PfDXS by intrinsic-tryptophan quenching titrations with 
increasing [pyruvate] and [GAP].
Battistini et al. Page 20
Protein Expr Purif. Author manuscript; available in PMC 2017 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 6. 
PvDXS double-reciprocal plots of initial velocities for pyruvate and GAP. (A) Velocities 
measured at fixed concentrations of GAP: 0.016 mM (★), 0.008 mM (●), 0.005 mM (■), 
0.0035 mM (▲). (B) Velocities measured at fixed concentrations of pyruvate: 0.25 mM (★), 
0.15 mM (●), 0.10 mM (■), and 0.05 mM (▲).
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Figure 7. 
PfDXS double-reciprocal plots of initial velocities for pyruvate and GAP. (A) Velocities 
measured at fixed concentrations of GAP: 0.016 mM (★), 0.008 mM (●), 0.005 mM (■), 
0.0035 mM (▲). (B) Velocities measured at fixed concentrations of pyruvate: 0.25 mM (★), 
0.15 mM (●), 0.10 mM (■), and 0.05 mM (▲).
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Figure 8. 
PvDXS global non-linear regression analysis for a random sequential mechanism. (A) 
Velocities measured at fixed concentrations of GAP: 0.016 mM (△), 0.008 mM (◊), 0.005 
mM (□), 0.0035 mM (○). (B) Velocities measured at fixed concentrations of pyruvate: 0.25 
mM (△), 0.15 mM (◊), 0.10 mM (□), and 0.05 mM (○).
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Figure 9. 
PfDXS global non-linear regression analysis for a random sequential mechanism. (A) 
Velocities measured at fixed concentrations of GAP: 0.016 mM (△), 0.008 mM (◊), 0.005 
mM (□), 0.0035 mM (○). (B) Velocities measured at fixed concentrations of pyruvate: 0.25 
mM (△), 0.15 mM (◊), 0.10 mM (□), and 0.05 mM (○).
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Figure 10. 
Inhibition of DXS by β-fluorpyruvate. (A) PvDXS assayed with varied concentrations of 
pyruvate at fixed concentrations of GAP (26 µM), in the presence of β-fluorpyruvate: 0 µM 
(●), 35 µM (○), and 75 µM (▼). (B) PvDXS assayed with varied concentrations of GAP at 
fixed concentrations of pyruvate (1.1 mM), in the presence of β-fluorpyruvate: 0 µM (●), 35 
µM (○), and 75 µM (▼). (C) PfDXS assayed with varied concentrations of pyruvate at fixed 
concentrations of GAP (16 µM), in the presence of β-fluorpyruvate: 0 µM (●), 50 µM (○), 
and 100 µM (▼). (D) PfDXS assayed with varied concentrations of GAP at fixed 
concentrations of pyruvate (640 µM), in the presence of β-fluorpyruvate: 0 µM (●), 50 µM 
(○), and 100 µM (▼).
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Figure 11. 
Inhibition of DXS by MAP. (A) PvDXS assayed with varied concentrations of pyruvate at 
fixed concentrations of GAP (26 µM), in the presence of MAP: 0 µM (●), 150 µM (○), and 
300 µM (▼). (B) PvDXS assayed with varied concentrations of GAP at fixed concentrations 
of pyruvate (1.1 mM), in the presence of MAP: 0 µM (●), 150 µM (○), and 300 µM (▼). (C) 
PfDXS assayed with varied concentrations of pyruvate at fixed concentrations of GAP (16 
µM), in the presence of MAP: 0 µM (●), 70 µM (○), and 140 µM (▼). (D) PfDXS assayed 
with varied concentrations of GAP at fixed concentrations of pyruvate (640 µM), in the 
presence of MAP: 0 µM (●), 70 µM (○), and 140 µM (▼).
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Table 2
Inhibition constants for β-fluoropyruvate and MAP against PvDXS and PfDXS
Enzyme Inhibitor Substrate Pattern Ki app (µM)
PvDXS
β-fluoropyruvate
Pyruvate Competitive 35 ± 1.7
GAP Noncompetitive 77 ± 7.2
MAP
Pyruvate Competitive 75 ± 5.0
GAP Noncompetitive 89 ± 6.7
PfDXS
β-fluoropyruvate
Pyruvate Competitive 43 ± 3.8
GAP Noncompetitive 131 ± 10
MAP
Pyruvate Competitive 46 ± 3.8
GAP Noncompetitive 103 ± 7.2
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